HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension.

AbstractPURPOSE:
To compare the 24-h IOP reductions induced by latanoprost, travoprost, and bimatoprost in eyes with exfoliation syndrome (XFS) associated with ocular hypertension (OH).
METHODS:
This was a prospective, randomized, single masked, and parallel design study with 15 patients in each treatment group. After washout of any previous medications, each patient underwent a baseline 24-h IOP curve testing at 0600, 0900, 1200, 1500, 1800, 2100, and at 2400 (midnight) hours. Patients were then randomized to receive latanoprost, travoprost, or bimatoprost once a day for 3 months. The 24-h curve testing was repeated at first week, and first and third months.
RESULTS:
Maximal and minimal IOP was recorded at 0600 and 1800-2100 hours. There was no significant difference among treatment groups at any time-point except for the first week. At the first week, the travoprost group had significantly lower IOP levels than the latanoprost and bimatoprost groups. All medicines significantly lowered 24-h IOP from baseline (P=0.001 for each). Although there was no significant difference in IOP reduction among groups at first week and first month, bimatoprost reduced the 24-h IOP (7.9+/-1.4) more than travoprost (6.6+/-0.5) at the end of the third month (P=0.003). The mean 24-h range of IOP was lowest with travoprost in all visits, and between-group differences was significant for travoprost vslatanoprost (P=0.007) and travoprost vsbimatoprost (P=0.001) at the third month.
CONCLUSION:
Latanoprost, travoprost, and bimatoprost were effective in reducing the 24-h IOP in patients with XFS and OH, and more research is required with a larger study.
AuthorsI F Hepsen, E Ozkaya
JournalEye (London, England) (Eye (Lond)) Vol. 21 Issue 4 Pg. 453-8 (Apr 2007) ISSN: 0950-222X [Print] England
PMID16543930 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Amides
  • Antihypertensive Agents
  • Lipids
  • Prostaglandins F, Synthetic
  • Cloprostenol
  • Latanoprost
  • Bimatoprost
  • Travoprost
Topics
  • Amides (therapeutic use)
  • Antihypertensive Agents (therapeutic use)
  • Bimatoprost
  • Cloprostenol (analogs & derivatives, therapeutic use)
  • Exfoliation Syndrome (drug therapy)
  • Female
  • Humans
  • Intraocular Pressure (drug effects)
  • Latanoprost
  • Lipids (therapeutic use)
  • Male
  • Middle Aged
  • Ocular Hypertension (drug therapy)
  • Prospective Studies
  • Prostaglandins F, Synthetic (therapeutic use)
  • Single-Blind Method
  • Travoprost
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: